Compare PACK & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | CCCC |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 350.6M |
| IPO Year | 2017 | 2020 |
| Metric | PACK | CCCC |
|---|---|---|
| Price | $3.18 | $3.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $7.08 | ★ $12.63 |
| AVG Volume (30 Days) | 613.1K | ★ 2.7M |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | $35,947,000.00 |
| Revenue This Year | $9.87 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | 1.02 |
| 52 Week Low | $3.05 | $1.69 |
| 52 Week High | $7.81 | $5.17 |
| Indicator | PACK | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 55.21 |
| Support Level | N/A | $2.55 |
| Resistance Level | $4.40 | $3.91 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 12.77 | 76.06 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.